THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.23]-CMP168 ID: TIP-MED-000438

Gamma Benzene Hexachloride (Lindane 1%) & Oral Ivermectin Scabies Protocol

Active Ingredient / Scientific Identity: Gamma Benzene Hexachloride • Class: Topical Synthetic Pyrethroid Ectoparasiticide (Scabicide & Pediculicide)

⚖️ Compare Profile
Generic / Entity NameGamma Benzene Hexachloride (Lindane 1%) & Oral Ivermectin Scabies Protocol ([12.23]-CMP168)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassTopical Synthetic Pyrethroid Ectoparasiticide (Scabicide & Pediculicide)
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: No adjustment required (rapidly hydrolysed by skin/plasma esterases). • Hepatic: No adjustment required.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Gamma Benzene Hexachloride (Lindane 1%) & Oral Ivermectin Scabies Protocol (TIP-MED-000438, Reference Code [12.23]-CMP168) is classified under Dermatological & Topical Antiseptic Preparations (Ch 12) as a Topical Synthetic Pyrethroid Ectoparasiticide (Scabicide & Pediculicide). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-12 (Option 12A; from reclassified HTML [12.26]). Lindane 1% carries neurotoxicity risk in infants/pregnancy; Oral Ivermectin ([8.12]) is used in crusted scabies.
Co-indexed per approved Author Decision DEC-12 (Option 12A; from reclassified HTML [12.26]). Lindane 1% carries neurotoxicity risk in infants/pregnancy; Oral Ivermectin ([8.12]) is used in crusted scabies.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-12 (Option 12A; from reclassified HTML [12.26]). Lindane 1% carries neurotoxicity risk in infants/pregnancy; Oral Ivermectin ([8.12]) is used in crusted scabies.

4. Therapeutic Indications & Evidence-Supported Uses

  • First-line treatment of scabies (Sarcoptes scabiei) and head/pubic lice (Pediculus humanus capitis / Pthirus pubis)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-12 (Option 12A; from reclassified HTML [12.26]). Lindane 1% carries neurotoxicity risk in infants/pregnancy; Oral Ivermectin ([8.12]) is used in crusted scabies.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [12.23].
Metabolism & Biotransformation:
Renal: No adjustment required (rapidly hydrolysed by skin/plasma esterases). • Hepatic: No adjustment required.
Elimination & Renal Adjustment:
Renal: No adjustment required (rapidly hydrolysed by skin/plasma esterases). • Hepatic: No adjustment required.
Hepatic Impairment Considerations:
Renal: No adjustment required (rapidly hydrolysed by skin/plasma esterases). • Hepatic: No adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Hypersensitivity to pyrethroids or chrysanthemums; infants <2 months (unless directed by specialist). • Precautions: FOR EXTERNAL USE ONLY. Post-scabetic pruritus (hypersensitivity reaction to dead mite antigens in epidermis) commonly persists for 2-4 weeks after successful eradication—do not repeatedly apply permethrin daily (causes irritative contact dermatitis); treat post-scabetic itch with oral antihistamines and emollients.

Key Clinical Precautions: Renal: No adjustment required (rapidly hydrolysed by skin/plasma esterases). • Hepatic: No adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Mild transient burning, stinging, tingling, or erythema at application site.
  • Allergic contact dermatitis, corneal irritation on accidental eye contact.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • No systemic drug interactions; avoid applying topical corticosteroids immediately before permethrin

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.23].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: MANDATORY 5-POINT SCABIES ERADICATION PROTOCOL: (1) Apply 5% cream to cool, dry skin from chin to toes (include under fingernails and between toes) and leave overnight for 8-14 hours, (2) Reapply if hands are washed during the night, (3) Treat ALL household members and close contacts on the SAME night even if they have no itch yet, (4) Wash bedsheets, towels, and clothes worn in past 3 days in hot water (>60°C) or seal in a plastic bag for 72 hours, (5) Repeat the second application exactly 7 days later.
    • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H / OTC | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / BNF 90th Ed

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Cream / Lotion (Scabies): 5% w/w (30 g, 60 g tube/bottle); Scalp Rinse / Lotion (Pediculosis): 1% w/w.

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.